Search

Dennis M Klinman

from Potomac, MD
Get Report
Related to:
Josh Frye, 74Emily R Rowe, 32Lisa L Klinman, 35Eva S Klinman, 36Johanna I Klinman, 32Desusan LeitmanSusan F Leitman, 72
Connected to:
Jerome J Klinman, 90Martin J Klinn, 73Anita R Klinner, 50Brent J Klinnert, 53Jeffrey P Klinnert, 63Shauna Klino, 36Jacob Klinski, 44Arnold I Klinsky, 81Fred E Klinsky, 91Lawrence A Klinsky, 58

Dennis Klinman Phones & Addresses

  • 2 Candlelight Ct, Potomac, MD 20854 (301) 983-2573 (301) 983-8163
  • Ventnor City, NJ

Work

Company: Dennis klinman 2019 Position: Consultant

Education

School / High School: Perelman School of Medicine University of Pennsylvania 1982

Skills

Research • Cell Biology • Molecular Biology • Medicine • Fda Regulatory Experience

Languages

English

Industries

Biotechnology

Specialities

Rheumatology

Professional Records

Medicine Doctors

Dennis Klinman Photo 1

Dennis M Klinman, Potomac MD

View page
Specialties:
Rheumatology
Address:
2 Candlelight Ct, Potomac, MD 20854
Languages:
English
Education:
Medical School
Perelman School of Medicine University of Pennsylvania
Graduated: 1982

Resumes

Resumes

Dennis Klinman Photo 2

Consultant

View page
Location:
Potomac, MD
Industry:
Biotechnology
Work:
Dennis Klinman
Consultant
National Cancer Institute (Nci)
Senior Investigator
Center For Biologics Evaluation and Research Us Food and Drug Administration 1989 - 2007
Section Chief
Education:
University of Pennsylvania School of Medicine 1976 - 1982
Doctor of Medicine, Doctorates, Doctor of Philosophy, Medicine Saint Joseph's University 1972 - 1976
Bachelors, Bachelor of Science, Biology
Skills:
Research
Cell Biology
Molecular Biology
Medicine
Fda Regulatory Experience

Publications

Us Patents

Oligodeoxynucleotide And Its Use To Induce An Immune Response

View page
US Patent:
6977245, Dec 20, 2005
Filed:
Feb 6, 2002
Appl. No.:
10/068160
Inventors:
Dennis Klinman - Potomac MD, US
Daniela Verthelyi - Potomac MD, US
Ken Ishii - Osaka, JP
James J. Mond - Silver Spring MD, US
Mayda Gursel - Rockville MD, US
Assignee:
The United States of America as represented by the Department of Health and Human Services - Washington DC
International Classification:
A61K048/00
US Classification:
514 44, 536 231, 536 255, 536 256
Abstract:
D type CpG oligodeoxynucleotides are provided herein that include a sequence represented by the following formula:5′XXXPuPyCpG PuPyXXX(W)(G)-3′wherein the central CpG motif is unmethylated, Pu is a purine nucleotide, Py is a pyrimidine nucleotide, X and W are any nucleotide, M is any integer from 0 to 10, and N is any integer from 4 to 10. Methods of using these oligodeoxynucleotides to induce an immune response are provided.

Method For Rapid Generation Of Mature Dendritic Cells

View page
US Patent:
7354909, Apr 8, 2008
Filed:
Aug 13, 2002
Appl. No.:
10/486755
Inventors:
Dennis M. Klinman - Potomac MD, US
Mayda Gursel - Ankara, TR
Daniela Verthelyi - Potomac MD, US
Assignee:
The United States of America as represented by Secretary of the Department of Health and Human Services - Washington DC
International Classification:
A61K 31/70
US Classification:
514 44, 536 231, 536 241
Abstract:
Novel methods for rapidly generating dendritic cells are disclosed herein. The methods include contacting a dendritic cell precursor with a D ODN to generate a mature dendritic cell. In one specific, non/limiting example, the method includes contacting the dendritic cell precursor or the mature dendritic cell with an antigen. The methods are of use both in vitro and in vivo.

Suppressors Of Cpg Oligonucleotides And Methods Of Use

View page
US Patent:
7514414, Apr 7, 2009
Filed:
Sep 24, 2002
Appl. No.:
10/489839
Inventors:
Dennis M. Klinman - Potomac MD, US
Rainald Zeuner - Kiel, GB
Mayda Gursel - Rockville MD, US
Ihsan Gursel - Rockville MD, US
Daniela Verthelyi - Potomac MD, US
Assignee:
The United States of America as represented by the Department of Health and Human Services - Washington DC
International Classification:
A61K 31/70
US Classification:
514 44, 536 243, 536 245, 536 231, 536 256
Abstract:
The present disclosure relates to oligodeoxynucleotides that suppress an immune response. Methods are disclosed for preventing or treating an immune-mediated disorder, such as, but not limited to, an autoimmune disease, by administering a therapeutically effective amount of a suppressive oligodeoxynucleotide. Also disclosed are methods of suppressing an immune response in a subject by administering a therapeutically effective amount of a suppressive oligodeoxynucleotide.

Method Of Treating Inflammatory Arthropathies With Suppressors Of Cpg Oligonucleotides

View page
US Patent:
7514415, Apr 7, 2009
Filed:
Jul 31, 2003
Appl. No.:
10/523273
Inventors:
Dennis Klinman - Potomac MD, US
Rainald Zeuner - Kiel, DE
Daniela Verthelyi - Potomac MD, US
Ihsan Gursel - Rockville MD, US
Mayda Gursel - Rockville MD, US
Assignee:
The United States of America as represented by the Department of Health and Human Services - Washington DC
International Classification:
A61K 31/70
US Classification:
514 44, 536 243, 536 245, 536 231, 536 256
Abstract:
The present disclosure relates to oligodeoxynucleotides that suppress an immune response. Methods are disclosed for preventing or treating inflammatory arthropathies by administering a therapeutically effective amount of a suppressive oligodeoxynucleotide.

Multiple Cpg Oligodeoxynucleotides And Their Use To Induce An Immune Response

View page
US Patent:
7521063, Apr 21, 2009
Filed:
Jul 12, 2002
Appl. No.:
10/194035
Inventors:
Dennis Klinman - Potomac MD, US
Ken Ishii - Columbia MD, US
Daniela Verthelyi - Potomac MD, US
Assignee:
The United States of America as represented by the Department of Health and Human Services - Washington DC
International Classification:
A61K 45/00
US Classification:
4242821, 4242781, 4242801, 514 44
Abstract:
Compositions including multiple oligodeoxynucleotides with a CpG motif are disclosed herein. The compositions can include either D or K type oligodeoxynucleotides. These compositions are of use in inducing an immune response in a large percentage of the individuals in a population.

Use Of Cpg Oligodeoxynucleotides To Induce Angiogenesis

View page
US Patent:
7615227, Nov 10, 2009
Filed:
Dec 19, 2002
Appl. No.:
10/499597
Inventors:
Dennis M. Klinman - Potomac MD, US
Mei Zheng - Augusta GA, US
Barry T. Rouse - Knoxville TN, US
Assignee:
The United States of America as represented by the Secretary of the Department of Health and Human Services - Washington DC
International Classification:
A61K 39/00
US Classification:
4241981
Abstract:
This disclosure provides a method of inducing production of vascular endothelial growth factor by a cell. The method includes contacting the cell with a CpG oligonucleotide, thereby inducing the production of vascular endothelial growth factor by the cell. The disclosure further provides a method inducing neovascularization in a tissue. This method includes comprising introducing a CpG oligodeoxynucleotide into an area of the tissue wherein the formation of new blood vessels is desired, thereby inducing neovascularization in the area of the tissue.

Use Of Sterically Stabilized Cationic Liposomes To Efficiently Deliver Cpg Oligonucleotides In Vivo

View page
US Patent:
7666674, Feb 23, 2010
Filed:
Jul 29, 2002
Appl. No.:
10/484991
Inventors:
Dennis M. Klinman - Potomac MD, US
Ihsan Gursel - Rockville MD, US
Ken J. Ishii - Osaka, JP
Assignee:
The United States of America as represented by the Secretary of the Department of Health and Human Services - Washington DC
International Classification:
C12N 5/00
C12N 5/02
A61K 9/127
A61K 31/70
A01N 43/04
US Classification:
435375, 424450, 435325, 514 44
Abstract:
Sterically stabilized cationic liposomes (SSCL) encapsulating a K type oligodeoxynucleotide (ODN) including a CpG motif are disclosed. These SSCL encapuslating a K type ODN can be used to effectively deliver the ODN to a cell. A novel method is also disclosed for producing the SSCL encapsulating the K type ODN. Administration of the SSCL encapsulating a K type ODN and a chemotherapeutic agent, such as a chimeric molecule comprising a targeting molecule selected from the group consisting of an IL-13, and an anti-IL-13 receptor antibody; and an effector molecule selected from the group consisting of a exotoxin, a Diphtheria toxin, and a radionuclide, can be used to dramatically reduce the growth of solid tumors.

Immunostimulatory Nucleic Acid Molecules

View page
US Patent:
7674777, Mar 9, 2010
Filed:
Jan 30, 2004
Appl. No.:
10/769282
Inventors:
Arthur M. Krieg - Wellesley MA, US
Dennis Klinman - Potomac MD, US
Alfred D. Steinberg - Potomac MD, US
Assignee:
University of Iowa Research Foundation - Iowa City IA
The United States of America as represented by the Department of Health and Human Services - Washington DC
Coley Pharmaceutical Group, Inc. - New York NY
International Classification:
A01N 61/00
A01N 37/18
A01N 43/04
C07H 21/04
C07H 21/02
A61K 39/38
A61K 39/00
A61K 45/00
A61K 47/00
A61K 31/00
A61K 38/00
A61K 9/127
US Classification:
514 44, 514 1, 514 2, 536 231, 536 242, 4241841, 4241851, 424450, 4242781
Abstract:
Nucleic acids containing unmethylated CpG dinucleotides and therapeutic utilities based on their ability to stimulate an immune response and to redirect a Th2 response to a Th1 response in a subject are disclosed. Methods for treating atopic diseases, including atopic dermatitis, are disclosed.
Control profile
Dennis M Klinman from Potomac, MD Get Report